GlassScriptPhysician profile
Barry A Noorda
NPI 1558351742
$1,845.64
in general payments reported to CMS, 2019-2025
30 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $300 · 2020: $259 · 2021: $339 · 2022: $289 · 2023: $177 · 2024: $171 · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $285.51 | 2019-2025 | |
| Astellas Pharma US INC | $221.27 | 2019-2025 | Veozah |
| Organon LLC | $156.25 | 2021-2025 | Nexplanon |
| Hologic Sales and Service, LLC | $116.56 | 2020-2025 | Myosure Tissue Removal Device, Novasure, Fluent Fluid Management System |
| Channel Medsystems, INC. | $111.15 | 2022 | |
| Exeltis, USA INC. | $106.73 | 2020-2025 | Slynd |
| Coopersurgical, INC. | $88.74 | 2019-2025 | Advincula Delineator Uterine Manipulator, Paragard T 380a |
| Sumitomo Pharma America, INC. | $81.58 | 2023-2025 | Myfembree, Gemtesa |
| Evofem Biosciences, INC. | $76.47 | 2021 | |
| Merck Sharp & Dohme LLC | $68.05 | 2019-2021 | |
| Ethicon US, LLC | $64.16 | 2019-2023 | Harmonic |
| Bayer Healthcare Pharmaceuticals INC. | $63.59 | 2019-2022 | |
| Boston Scientific Corporation | $49.01 | 2020-2021 | |
| Therapeuticsmd, INC. | $42.77 | 2019-2020 | |
| Conmed Corporation | $42.23 | 2024-2025 | Airseal |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $38.35 | 2021-2022 | |
| Aspira Women'S Health INC | $32.77 | 2021 | |
| Allergan, INC. | $25.85 | 2019 | |
| Coloplast Corp | $18.96 | 2025 | |
| Roche Diagnostics Corporation | $18.06 | 2021 | |
| Biogen, INC. | $15.85 | 2025 | Zurzuvae |
| Dexcom, INC. | $15.01 | 2025 | Dexcom G6 Transmitter |
| C. R. Bard, INC. & Subsidiaries | $14.54 | 2024 | Bd Onclarity |
| Si-Bone, INC. | $14.44 | 2019 | |
| Ascend Therapeutics US, LLC | $13.98 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.93 | 2019 | |
| Sage Therapeutics, LLC | $13.20 | 2020 | |
| Novo Nordisk INC | $12.98 | 2023 | |
| Mayne Pharma Commercial LLC | $12.85 | 2023 | |
| Meditrina | $10.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barry Noorda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.